These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22742815)

  • 1. Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib.
    Caocci G; Maioli MA; Atzeni S; Piras R; Carboni N; La Nasa G
    Leuk Res; 2012 Sep; 36(9):e206-8. PubMed ID: 22742815
    [No Abstract]   [Full Text] [Related]  

  • 2. Intramuscular edema as a complication of treatment with imatinib.
    Shimazaki C; Ochiai N; Uchida R; Fuchida SI; Okano A; Ashihara E; Inaba T; Fujita N; Nakagawa M
    Leukemia; 2003 Apr; 17(4):804-5. PubMed ID: 12682642
    [No Abstract]   [Full Text] [Related]  

  • 3. Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental?
    Gopaluni S; Sanyal S; Bair A; Vajpayee N
    J Clin Oncol; 2012 Feb; 30(5):e58-61. PubMed ID: 22184394
    [No Abstract]   [Full Text] [Related]  

  • 4. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.
    Zakrzewski D; Seferynska I; Warzocha K; Hryniewiecki T
    Int J Hematol; 2012 Jul; 96(1):132-5. PubMed ID: 22639052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.
    Breccia M; Colafigli G; Molica M; Alimena G
    Am J Hematol; 2015 May; 90(5):E100-1. PubMed ID: 25683643
    [No Abstract]   [Full Text] [Related]  

  • 6. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
    Delomas T; Darné C; Besson C
    Leuk Lymphoma; 2012 Feb; 53(2):332-3. PubMed ID: 21823828
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage.
    Donatelli C; Chongnarungsin D; Ashton R
    Leuk Lymphoma; 2014 Oct; 55(10):2408-9. PubMed ID: 24467220
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 10. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
    Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
    Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.
    Rea D; Mirault T; Raffoux E; Boissel N; Andreoli AL; Rousselot P; Dombret H; Messas E
    Leukemia; 2015 May; 29(5):1206-9. PubMed ID: 25482133
    [No Abstract]   [Full Text] [Related]  

  • 12. The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Mori H; Sukegawa M; Fukatsu M; Sano T; Takahashi H; Harada K; Kimura S; Ohkawara H; Nakamura K; Mita M; Saito T; Hamazaki Y; Ohta M; Ikezoe T
    Ann Hematol; 2020 Feb; 99(2):359-361. PubMed ID: 31872359
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 14. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
    Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
    Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
    [No Abstract]   [Full Text] [Related]  

  • 15. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib (Tasigna) for CML.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):26-7. PubMed ID: 18391899
    [No Abstract]   [Full Text] [Related]  

  • 18. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.
    Angelopoulou MK; Asimakopoulos JV; Galani Z; Levidou G; Roumelioti M; Vassilakopoulos TP; Korkolopoulou P; Panayiotidis P
    Blood Cancer J; 2016 Aug; 6(8):e461. PubMed ID: 27564459
    [No Abstract]   [Full Text] [Related]  

  • 20. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.